Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

Detalles Bibliográficos
Autores principales: Fitzgerald, Timothy, Zhdanava, Maryia, Pilon, Dominic, Shah, Aditi, Lefebvre, Patrick, Feldman, Steven R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613165/
https://www.ncbi.nlm.nih.gov/pubmed/37752408
http://dx.doi.org/10.1007/s13555-023-01017-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613165/
https://www.ncbi.nlm.nih.gov/pubmed/37752408
http://dx.doi.org/10.1007/s13555-023-01017-8

Ejemplares similares